文献速递临床试验与 GCP

钠-葡萄糖协同转运蛋白2抑制剂对急性心肌梗死患者心脏自主神经活性及心室重构的影响:一项临床试验的研究方案

Effects of SGLT2 inhibitors on cardiac autonomic activity and ventricular remodeling in patients with acute myocardial infarction: study protocol for a clinical trial.
PubMed 文献 · Trials · 2025-07-14

本研究为在中国开展的前瞻性、随机、开放标签、评估者盲法、单中心试验,计划纳入110例急性心肌梗死患者,按1:1随机分配至仅接受标准化治疗或标准化治疗联合达格列净10 mg每日一次。主要终点为基线至24周时经24小时动态心电图测定的心率变异性及减速能力变化,次要终点包括左心室重构指数变化及随访期间主要不良心血管事件发生率。

要点

  • 计划纳入110例急性心肌梗死患者,1:1随机分配至标准化治疗或联合达格列净10 mg每日一次。
  • 主要终点为基线至24周心率变异性及减速能力的变化。
  • 次要终点包括左心室重构指数变化及随访期间主要不良心血管事件发生率。

核心结论

  • 本研究旨在填补达格列净对急性心肌梗死患者心脏自主神经活性及心室重构影响的知识空白。
  • 研究者称本研究将是首个评估达格列净对急性心肌梗死患者心脏自主神经功能及心室重构影响的试验。
  • 研究者希望阐明达格列净心脏保护作用的机制,可能为改善该人群预后的未来治疗策略提供信息。

研究设计与样本

  • 前瞻性、随机、开放标签、评估者盲法、单中心试验,在中国急性心肌梗死患者中开展。
  • 计划纳入110例参与者,按1:1比例随机分配至仅接受标准化治疗组或标准化治疗联合达格列净10 mg每日一次组。

主要发现

  • 主要终点为基线至24周时经24小时动态心电图测定的心率变异性及减速能力的变化。
  • 次要终点包括左心室重构指数(左心室舒张末期容积的相对变化,LVRI)较基线的变化,以及整个随访期间主要不良心血管事件的发生率。
  • 还将分析基线至24周时血糖、血脂、血压、体重及与急性心肌梗死诊断和功能参数相关的生物标志物(如肌酸激酶、肌钙蛋白I及N末端B型利钠肽原)的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) exhibit significant cardiovascular protective effects in patients with acute myocardial infarction (AMI) complicated with type 2 diabetes mellitus (T2DM), mainly through enhancing cardiac function and reducing malignant arrhythmias. However, limited evidence exists regarding their efficacy in non-diabetic AMI patients. Moreover, the relationship between these benefits and improvements in cardiac autonomic function and left ventricular remodeling remains contentious, hindering a comprehensive understanding of their mechanisms of action. This study aims to fill this knowledge gap regarding dapagliflozin's effects on cardiac autonomic activity and ventricular remodeling in AMI patients. METHODS: This study is a prospective, randomized, open-label, assessor-blinded, single-center trial in AMI patients in China. A total of 110 participants will be randomly allocated in a 1:1 ratio to either receive standardized treatment alone or receive standardized treatment along with 10 mg of dapagliflozin taken once daily. The primary endpoint is the change from the baseline to 24 weeks in heart rate variability (HRV) and deceleration capacity (DC) measured by 24-h ambulatory Holter monitoring. Secondary endpoints include changes in the left ventricular remodeling index (a relative change of LV end-diastolic volume, LVRI) as measured from baseline, along with the incidence of major adverse cardiovascular events throughout the follow-up period. Changes in various variables from the baseline will also be analyzed, encompassing glucose and lipid levels, blood pressure, body weight, and biomarkers linked to diagnostic and functional parameters of AMI, such as creatine kinase, troponin I (TnI) level, and N terminal pro B type natriuretic peptide (NT-proBNP) level. DISCUSSION: This will be the first trial to evaluate the effects of dapagliflozin on cardiac autonomic function and ventricular remodeling in AMI patients. This study seeks to elucidate the mechanisms underlying dapagliflozin's cardioprotective effects, potentially informing future therapeutic strategies for improving outcomes in this population. TRIAL REGISTRATION: Clinical trial ID: ChiCTR2400084050. Registration date: May 9, 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wan J, Zhang Q, Xu F, et al. Effects of SGLT2 inhibitors on cardiac autonomic activity and ventricular remodeling in patients with acute myocardial infarction: study protocol for a clinical trial. Trials. 2025. PMID: 40660363. doi:10.1186/s13063-025-08956-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。